Comparative Pharmacology
Head-to-head clinical analysis: NEULASTA versus RELEUKO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEULASTA versus RELEUKO.
NEULASTA vs RELEUKO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pegfilgrastim is a recombinant methionyl human granulocyte colony-stimulating factor (G-CSF) conjugated to polyethylene glycol. It binds to G-CSF receptors on hematopoietic progenitor cells, stimulating proliferation, differentiation, and release of neutrophils from the bone marrow.
Recombinant human granulocyte colony-stimulating factor (G-CSF) that stimulates proliferation, differentiation, and activation of neutrophil progenitor cells.
6 mg subcutaneously once per chemotherapy cycle, administered at least 24 hours after cytotoxic chemotherapy and at least 14 days before next cycle.
5 mcg/kg subcutaneously once daily for up to 10 days or until neutrophil count >10,000/mcL after nadir.
None Documented
None Documented
Terminal elimination half-life is approximately 15-23 hours (mean ~18 hours) in healthy subjects, allowing for once-per-cycle dosing for chemotherapy-induced neutropenia.
Terminal half-life approximately 5.3 hours (range 4.5–6.2 hours) in adults with normal renal function.
Primarily renal clearance (through glomerular filtration and proteolytic degradation). Approximately 80% of the dose is eliminated renally as degraded peptides.
Primarily renal (approximately 70% as intact drug). Minor biliary/fecal elimination (<5%).
Category C
Category C
Colony-Stimulating Factor
Colony-Stimulating Factor